Richard S. Geary - Jan 18, 2022 Form 4 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
EVP, Chief Development Officer
Signature
By: Patrick R. O'Neil, attorney-in-fact For: Richard S. Geary
Stock symbol
IONS
Transactions as of
Jan 18, 2022
Transactions value $
-$229,063
Form type
4
Date filed
1/20/2022, 07:16 PM
Previous filing
Jan 19, 2022
Next filing
Mar 2, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IONS Common Stock Options Exercise $0 +21.4K +50.97% $0.00 63.4K Jan 18, 2022 Direct F1
transaction IONS Common Stock Tax liability -$229K -7.61K -12% $30.12 55.8K Jan 18, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IONS Restricted Stock Unit Options Exercise $0 -21.4K -29.61% $0.00 50.9K Jan 18, 2022 Common Stock 21.4K $0.00 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquired pursuant to vesting and release of shares in accordance with Restricted Stock Unit awards.
F2 Shares withheld to cover the required tax withholding obligations pursuant to the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
F3 Each Restricted Stock Unit represents a contingent right to receive one share of Ionis common stock, or its equivalent cash value.
F4 Restricted Stock Units vest in four equal annual installments. Upon vesting, the Restricted Stock Units will be paid out in whole shares of Ionis common stock or cash as may be determined by Ionis.